Zynerba Pharmaceuticals Inc (ZYNE) Shares Bought by Pennsylvania Trust Co

Pennsylvania Trust Co grew its holdings in shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) by 17.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 202,100 shares of the company’s stock after buying an additional 30,000 shares during the quarter. Pennsylvania Trust Co’s holdings in Zynerba Pharmaceuticals were worth $1,649,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. boosted its stake in shares of Zynerba Pharmaceuticals by 385.6% during the 1st quarter. JPMorgan Chase & Co. now owns 12,217 shares of the company’s stock valued at $106,000 after buying an additional 9,701 shares during the last quarter. Raymond James & Associates purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at approximately $164,000. Engineers Gate Manager LP purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at approximately $231,000. Jane Street Group LLC purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at approximately $239,000. Finally, LMR Partners LLP purchased a new position in shares of Zynerba Pharmaceuticals during the 2nd quarter valued at approximately $312,000. Institutional investors own 14.22% of the company’s stock.

Shares of ZYNE opened at $7.00 on Thursday. Zynerba Pharmaceuticals Inc has a 12-month low of $5.59 and a 12-month high of $15.14. The firm has a market cap of $143.81 million, a P/E ratio of -2.86 and a beta of 4.52.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its quarterly earnings data on Thursday, August 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.12). On average, analysts predict that Zynerba Pharmaceuticals Inc will post -3.1 EPS for the current fiscal year.

Several equities analysts have recently commented on ZYNE shares. HC Wainwright set a $23.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, July 13th. Canaccord Genuity set a $18.00 price objective on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, July 13th. Cantor Fitzgerald set a $20.00 price objective on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, July 5th. Finally, ValuEngine upgraded Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Zynerba Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $18.93.

In related news, CFO James E. Fickenscher bought 8,518 shares of the business’s stock in a transaction on Monday, August 6th. The shares were bought at an average cost of $5.97 per share, for a total transaction of $50,852.46. Following the completion of the purchase, the chief financial officer now owns 20,718 shares of the company’s stock, valued at approximately $123,686.46. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Armando Anido bought 15,000 shares of the business’s stock in a transaction on Monday, August 6th. The stock was bought at an average price of $5.96 per share, for a total transaction of $89,400.00. Following the completion of the purchase, the chairman now directly owns 352,512 shares of the company’s stock, valued at approximately $2,100,971.52. The disclosure for this purchase can be found here. Insiders have purchased 32,318 shares of company stock worth $194,404 over the last 90 days. 12.67% of the stock is currently owned by company insiders.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.

Read More: Stop Order

Want to see what other hedge funds are holding ZYNE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE).

Institutional Ownership by Quarter for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply